


Discovery of small-molecule drug candidates for the treatment of Fibrostenotic Crohn's Disease(FSCD)

IMMUNOLOGY	Candidate
Product Type	Small molecules
Indication	Fibrostenotic crohn's disease(FSCD)
Target	Transglutaminase2(TG2)
MoA(Mechanism of Action)	<i>HUC1A-626</i>, a selective calcium-activated Transglutaminase2(TG2), directly modulates ECM deposition and remodeling by preventing enzymatic cross-linking of matrix proteins. 
Competitiveness	- HUC1A-626 directly inhibits ECM cross-linking, reducing tissue stiffness and representing a therapeutic target with potential efficacy in patients with advanced fibrosis. - HUC1A-626 formed an irreversible bond with its target protein TG2, thereby prolonging the duration of inhibition. - HUC1A-626 exhibits a pharmacokinetic profile characterized by sustained high concentrations in the intestine and limited systemic exposure.
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.